nifuroxazide | Enterofuril suspension 200 mg / 5 ml, 90 ml
Special Price
$19.40
Regular Price
$28.00
In stock
SKU
BID463097
Release form
Suspension for oral administration.
Suspension for oral administration.
Release form
Suspension for oral administration.
Packing
90 ml.
Pharmacological action of
Enoxaparia sodium - low molecular weight heparin. The average molecular weight is about 4,500 daltons: less than 2,000 daltons -68%, more than 8,000 daltons - <18%. Enoxaparium sodium is obtained by alkaline hydrolysis of heparin gasoline ester isolated from the mucous membrane of the pig’s small intestine. Its structure is characterized by a non-reducing fragment of 2-0-sulfo-4-enpyrazinosuronic acid and a recovering fragment of 2-14.6-0-disulfo-0-glucopyranoside.
The structure of sodium enoxaparin contains about 20% (ranging from 15% to 25%) of the 1,6-anhydron derivative in the reducing fragment of the polysaccharide chain.
Pharmacodynamics of
In vitro sodium enoxaparium has high activity against coagulation factor Xa (anti-Xa activity of approximately 100 IU / ml) and low activity against coagulation factor (ant-IIa or anti-thrombin activity of approximately 28 IU / ml). This anticoagulant activity is mediated by antithrombin III (AT-III). In addition to the anti-Xa / IIa activity, additional anticoagulant and anti-inflammatory properties of enoxaparp sodium were also detected both in humans and in animal models, which include AT-III-dependent inhibition of other coagulation factors, such as Vila factor, activation of tissue factor pathway inhibitor release, and also a decrease in the release of von Willebrand factor from vascular endothelium into the bloodstream. These factors provide the anticoagulant effect of enoxaparin sodium in general.
When used in prophylactic doses, epoxaparin sodium slightly changes the activated partial thromboplas type time (APTT). has virtually no effect on platelet aggregation and the degree of binding of fibrinogen to platelet receptors.
Anti-IIa activity in plasma is about 10 times lower than anti-Xa activity.
The average maximum anti-IIa activity is observed approximately 3-4 hours after subcutaneous administration and reaches 0.13 IU / ml and 0.19 IU / ml after repeated administration of 1 mg / kg of body weight - with double administration and 1.5 mg / kg of body weight body - with a single administration, respectively. The average maximum anti-Xa plasma activity is observed 3-5 hours after subcutaneous administration of the drug and is approximately 0.2 0.4 1.0 and 1.3 anti-XA ME / ml after subcutaneous administration of 20 mg, 40 mg and 1 mg / kg and 1,systemic effect and used to treat diarrhea of infectious etiology.
Enterofuril® contains the active substance nifuroxazide, a drug of the 5-nitrofuran group of derivatives. The drug has a bactericidal and bacteriostatic effect against most pathogens of acute intestinal infections. The antimicrobial effect of nifuroxazide is dose-dependent: for example, low and medium doses of the drug have a bacteriostatic effect against pathogenic microflora, and high ones have a bactericidal effect.
The bacteriostatic mechanism of action of the drug is associated with inhibition of the activity of the enzyme dehydrogenase, which leads to disruption of the normal course of synthesis of vital compounds in the cell of the microorganism.
So due to the influence of nifuroxazide on the cell of the microorganism, there is a violation of the respiratory chain, inhibition of the tricarboxylic acid cycle. In addition, Enterofuril® inhibits the synthesis of proteins in the cell of the microorganism and inhibits other biochemical processes in the bacterial cell. Thus, the cell of the microorganism loses its ability to reproduce.
Indications
Diarrhea of bacterial origin, chronic gastrointestinal lesions of bacterial etiology, accompanied by dyspeptic phenomena.
Contraindications
- Hypersensitivity to nitrofuran derivatives or other components of the
preparation - fructose intolerance, glucose-galactose malabsorption syndrome or sucrose and
isomaltase deficiency - neonatal period (up to 1 month), prematurity.
Special instructions
When treating diarrhea concomitantly with nifuroxazide therapy, rehydration therapy (oral or intravenous) must be carried out in accordance with the patient's condition and the intensity of diarrhea.
The use of alcohol during nifuroxazide therapy is prohibited.
Before prescribing a suspension in infants, it is necessary to exclude their congenital deficiency of enzymes that break down sucrose.
Effect on the ability to drive vehicles and work with mechanisms
The drug does not affect psychomotor activity and the ability to drive vehicles and work with mechanisms.
Composition of
5 ml oral suspension contains:
active ingredient:
nifuroxazide 200 mg,
excipients:
sucrose - 1000 mg
sodium hydroxide - 2 mg
methyl parahydroxybenzoate - 5 mg 5 mg - 5 mg
carbomer - 10.5 mg
citric acid - 0.75 mg
banana flavor - 10 mg
water - up to 5 ml
Dosage and Administration
Inside.
Nifuroxazide therapy should not be continued for more than 7 days. For dosing, a 5 ml dosage spoon is used, having a graduation of 2.5 ml. Before use, the suspension must be shaken well.
Children 1–6 months of age: 2.5 ml 2-3 times a day (with an interval of 8 to 12 hours).
Children 7 months - 2 years: 2.5 ml 4 times a day (with an interval of 8 hours).
Children 3–7 years of age: 5 ml 3 times a day (with an interval of 8 hours).
Adults and children over 7 years of age: 5 ml 3-4 times a day (with an interval of 6-8 hours).
Side effects
Allergic reactions (rash, urticaria, Quincke's edema, anaphylactic shock), nausea, vomiting.
Overdose
The drug is not absorbed from the digestive tract and does not enter the systemic circulation.
Overdose symptoms not known.
If the dose is exceeded, gastric lavage and symptomatic treatment are recommended.
Storage Conditions
At 15 to 30 РC.
Expiration
3 years. The opened vial should be stored for a maximum of 14 days.
Active ingredient
nifuroxazide
Conditions for dispensing from pharmacies
Without a prescription
Lekarstvennaja form
suspensions for pryema inside
Bosnalek, Bosnia and Herzegovina
Suspension for oral administration.
Packing
90 ml.
Pharmacological action of
Enoxaparia sodium - low molecular weight heparin. The average molecular weight is about 4,500 daltons: less than 2,000 daltons -68%, more than 8,000 daltons - <18%. Enoxaparium sodium is obtained by alkaline hydrolysis of heparin gasoline ester isolated from the mucous membrane of the pig’s small intestine. Its structure is characterized by a non-reducing fragment of 2-0-sulfo-4-enpyrazinosuronic acid and a recovering fragment of 2-14.6-0-disulfo-0-glucopyranoside.
The structure of sodium enoxaparin contains about 20% (ranging from 15% to 25%) of the 1,6-anhydron derivative in the reducing fragment of the polysaccharide chain.
Pharmacodynamics of
In vitro sodium enoxaparium has high activity against coagulation factor Xa (anti-Xa activity of approximately 100 IU / ml) and low activity against coagulation factor (ant-IIa or anti-thrombin activity of approximately 28 IU / ml). This anticoagulant activity is mediated by antithrombin III (AT-III). In addition to the anti-Xa / IIa activity, additional anticoagulant and anti-inflammatory properties of enoxaparp sodium were also detected both in humans and in animal models, which include AT-III-dependent inhibition of other coagulation factors, such as Vila factor, activation of tissue factor pathway inhibitor release, and also a decrease in the release of von Willebrand factor from vascular endothelium into the bloodstream. These factors provide the anticoagulant effect of enoxaparin sodium in general.
When used in prophylactic doses, epoxaparin sodium slightly changes the activated partial thromboplas type time (APTT). has virtually no effect on platelet aggregation and the degree of binding of fibrinogen to platelet receptors.
Anti-IIa activity in plasma is about 10 times lower than anti-Xa activity.
The average maximum anti-IIa activity is observed approximately 3-4 hours after subcutaneous administration and reaches 0.13 IU / ml and 0.19 IU / ml after repeated administration of 1 mg / kg of body weight - with double administration and 1.5 mg / kg of body weight body - with a single administration, respectively. The average maximum anti-Xa plasma activity is observed 3-5 hours after subcutaneous administration of the drug and is approximately 0.2 0.4 1.0 and 1.3 anti-XA ME / ml after subcutaneous administration of 20 mg, 40 mg and 1 mg / kg and 1,systemic effect and used to treat diarrhea of infectious etiology.
Enterofuril® contains the active substance nifuroxazide, a drug of the 5-nitrofuran group of derivatives. The drug has a bactericidal and bacteriostatic effect against most pathogens of acute intestinal infections. The antimicrobial effect of nifuroxazide is dose-dependent: for example, low and medium doses of the drug have a bacteriostatic effect against pathogenic microflora, and high ones have a bactericidal effect.
The bacteriostatic mechanism of action of the drug is associated with inhibition of the activity of the enzyme dehydrogenase, which leads to disruption of the normal course of synthesis of vital compounds in the cell of the microorganism.
So due to the influence of nifuroxazide on the cell of the microorganism, there is a violation of the respiratory chain, inhibition of the tricarboxylic acid cycle. In addition, Enterofuril® inhibits the synthesis of proteins in the cell of the microorganism and inhibits other biochemical processes in the bacterial cell. Thus, the cell of the microorganism loses its ability to reproduce.
Indications
Diarrhea of bacterial origin, chronic gastrointestinal lesions of bacterial etiology, accompanied by dyspeptic phenomena.
Contraindications
- Hypersensitivity to nitrofuran derivatives or other components of the
preparation - fructose intolerance, glucose-galactose malabsorption syndrome or sucrose and
isomaltase deficiency - neonatal period (up to 1 month), prematurity.
Special instructions
When treating diarrhea concomitantly with nifuroxazide therapy, rehydration therapy (oral or intravenous) must be carried out in accordance with the patient's condition and the intensity of diarrhea.
The use of alcohol during nifuroxazide therapy is prohibited.
Before prescribing a suspension in infants, it is necessary to exclude their congenital deficiency of enzymes that break down sucrose.
Effect on the ability to drive vehicles and work with mechanisms
The drug does not affect psychomotor activity and the ability to drive vehicles and work with mechanisms.
Composition of
5 ml oral suspension contains:
active ingredient:
nifuroxazide 200 mg,
excipients:
sucrose - 1000 mg
sodium hydroxide - 2 mg
methyl parahydroxybenzoate - 5 mg 5 mg - 5 mg
carbomer - 10.5 mg
citric acid - 0.75 mg
banana flavor - 10 mg
water - up to 5 ml
Dosage and Administration
Inside.
Nifuroxazide therapy should not be continued for more than 7 days. For dosing, a 5 ml dosage spoon is used, having a graduation of 2.5 ml. Before use, the suspension must be shaken well.
Children 1–6 months of age: 2.5 ml 2-3 times a day (with an interval of 8 to 12 hours).
Children 7 months - 2 years: 2.5 ml 4 times a day (with an interval of 8 hours).
Children 3–7 years of age: 5 ml 3 times a day (with an interval of 8 hours).
Adults and children over 7 years of age: 5 ml 3-4 times a day (with an interval of 6-8 hours).
Side effects
Allergic reactions (rash, urticaria, Quincke's edema, anaphylactic shock), nausea, vomiting.
Overdose
The drug is not absorbed from the digestive tract and does not enter the systemic circulation.
Overdose symptoms not known.
If the dose is exceeded, gastric lavage and symptomatic treatment are recommended.
Storage Conditions
At 15 to 30 РC.
Expiration
3 years. The opened vial should be stored for a maximum of 14 days.
Active ingredient
nifuroxazide
Conditions for dispensing from pharmacies
Without a prescription
Lekarstvennaja form
suspensions for pryema inside
Bosnalek, Bosnia and Herzegovina
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review